Diastolic wall motion abnormality after myocardial infarction: relation to neurohormonal activation and prognostic

Mirza Husic1, Betina Nørager, Kenneth Egstrup

  • 1Department of Medicine, Svendborg Hospital, Svenborg, Denmark.

American Heart Journal
|October 8, 2005
PubMed

Insights

Diastolic wall motion abnormality (WMA) after acute myocardial infarction (AMI) is common and detectable early. This diastolic WMA predicts adverse outcomes and is linked to neurohormonal activation.

Area of Science:

  • Cardiology
  • Echocardiography
  • Myocardial Infarction

Background:

  • Systolic wall motion abnormality (WMA) is a known outcome predictor post-acute myocardial infarction (AMI).
  • The role and detection of diastolic WMA after AMI were previously unknown.
  • This study investigated diastolic WMA using color kinesis.

Purpose of the Study:

  • To detect diastolic WMA early after AMI using color kinesis.
  • To assess the relationship between diastolic WMA and neurohormonal activation.
  • To evaluate the prognostic significance of diastolic WMA in patients with first AMI.

Main Methods:

  • 149 patients with first AMI underwent color kinesis and echocardiography within 24 hours.
  • N-terminal pro-brain natriuretic peptide levels were measured 3 days post-AMI.
  • The study endpoint was cardiac death or heart failure readmission.

Main Results:

  • Diastolic WMA exceeded systolic WMA in 97% of patients.
  • Diastolic WMA correlated significantly with brain natriuretic peptide and coronary artery disease severity.
  • Diastolic WMA independently predicted cardiac death or heart failure readmission.

Conclusions:

  • Color kinesis effectively assesses diastolic WMA early after AMI.
  • Diastolic WMA is linked to neurohormonal activation and coronary artery disease severity.
  • Diastolic WMA provides independent prognostic information in AMI patients.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...